ClinicalTrials.gg
Not yet recruitingNCT07004725Updated Jun 4, 2025

Therapy of Niacin for Rheumatoid Arthritis

A Phase 2 interventional study of niacin sustained release capsules and Placebo in Rheumatoid Arthritis (RA), sponsored by Peking University People's Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by Peking University People's Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Arthritis, Rheumatoid by Peking University People's Hospital — 5 open to participants now, 5 under way, none of them phase 3. Arthritis, Rheumatoid · Peking University People's Hospital.

Started
2025
with 1 other
Phase 2
5 of 12
2 open now
Registered
7th of 12
by date

Among the 12 studies in Arthritis, Rheumatoid by Peking University People's Hospital, this one is one of 2 that started in 2025, is one of 5 in phase 2, and was the 7th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 12 studies in Arthritis, Rheumatoid by Peking University People's Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Arthritis, Rheumatoid by Peking University People's Hospital, or all of them as a file.
02

Study summary

This study is a study to evaluate the safety and efficacy of administering niacin sustained-release capsules to rheumatoid arthritis with hyperlipidemia patients. Sixty patients were randomly assigned to niacin or placebo for 12 weeks, followed by niacin for 12 weeks. Changes in disease activity score, immune cell subtypes, markers of intestinal damage, intestinal flora, and other laboratory indicators will be monitored.

Read the detailed description

In this study, a randomized double-blind placebo study was conducted to treat patients with rheumatoid arthritis (RA) complicated with dyslipidemia with niacin sustained-release capsules. This study intends to include 60 patients, who are randomly divided into the control group and niacin group in a 1:1 ratio. With the basic treatment of RA unchanged, the administration plan of the two groups is as follows: divided into two stages, the first stage: the niacin group is given a niacin sustained-release capsule orally for 3 months, and the control group is given a placebo orally for 3 months. The second stage: Both groups were given niacin sustained-release capsules for 3 months.The primary endpoint was the change of immune cell subsets, which clarified the immunomodulatory effect of niacin. The secondary end point was to observe the changes in blood lipid, improvement of joint symptoms, effect on intestinal barrier, the effect on intestinal flora, and safety of taking niacin sustained-release capsules.

03

Conditions studied

  • Rheumatoid Arthritis (RA)

Keywords

  • Rheumatoid Arthritis (RA)
  • niacin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥18 years of age at the time of screening, weight≥35 kg.
  • Diagnosed with rheumatoid arthritis satisfying the 1987 American College of Rheumatology classification criteria or ACR/EULAR 2010 classification criteria.
  • Stable treatment, including DMARDs (disease-modifying anti-rheumatic drugs) and , was stable in dose for at least 4 weeks, and no biological agents were used during the first 12 weeks of enrollment.
  • Dyslipidemia (5.2≤TC≤7.2mmol/L, 3.4≤LDL-c≤4.9mmol/L or 1.7≤TG≤5.1 mmol/L)
  • Have given written .

Exclusion criteria

Exclusion Criteria:

  • a. Patients with other diseases (such as systemic lupus erythematosus, Sjogren's syndrome, ankylosing spondylitis, etc.).
  • b. Patients with uncontrolled hyperuricemia and gout.
  • c. Patients who take lipid-lowering drugs such as statins or fibrates orally, cardiovascular medications (such as aspirin, nitrates, calcium channel blockers, epinephrine blockers).
  • d. Patients with Stevens-Johnson syndrome, toxic epidermal necrolysis, or multiple erythema.
  • e. Patients with significantly impaired bone marrow function or significant anemia, leukopenia, or thrombocytopenia, excepting those secondary to active rheumatoid arthritis.
  • f. Persistent or severe infection within 3 months prior to enrollment.
  • g. Uncontrolled high blood pressure, diabetes, atherosclerotic cardiovascular disease, inflammatory bowel disease, peptic ulcer and other digestive diseases, end-stage diseases, or diseases that investigators believe would put patients at risk for study participation.
  • h. cardiovascular, liver, neurological, endocrine, or other major systemic disease that makes the implementation of the protocol or the interpretation of the findings difficult.
  • i. Severe liver and kidney function impairment (severe hypoproteinemia with serum albumin \<30g/L, elevated aminotransferase more than 2 times the , moderate or severe renal function impairment, such as creatinine >133 μ/L, etc.).
  • j. Patients with a recent and clinically severe history of drug or alcohol abuse.
  • k. Pregnant.
  • l. Breastfeeding.
  • m. Subjects who wish to become fathers during the study or within 24 months (or 3 months ) after the study;
  • n. Patients with congenital or acquired severe immunodeficiency, a history of cancer or lymphoproliferative disease, or patients who have received total lymphoid radiation.
  • o. Known -positive status.
  • p. Patients with known or positive serology and patients with hepatobiliary diseases such as chronic active liver disease.
  • q. Use any biologics, such as anti-tumor necrosis factor, abaxipril, tuximab, or rituximab, within 3 months prior to the first dose.
  • r. Enroll in any other clinical trial involving the off-label use of drugs or devices, or enroll in any other type of medical research.
  • s. (BMI) less than 18.5kg/m2 or greater than 30 kg/m2.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Niacin

    The first and second stage: niacin sustained-release capsules orally for 3 months

    Drug: niacin sustained release capsules

  • Placebo comparator
    Placebo

    The first stage: placebo for 3 months, the second stage: niacin sustained release capsules for 3 months

    Drug: Placebo

Interventions

  • Drugniacin sustained release capsules

    The first stage: the niacin group was given niacin sustained-release capsules for 3 months, and the control group was given placebo for 3 months. The second stage: Both groups were given niacin sustained-release capsules for 3 months. Dosage of niacin sustained-release capsules and placebo: 500mg once a day for week 1-4; The dose is 1000mg once a day for 5 to 12 weeks

  • DrugPlacebo

    The group was given oral placebo for 3 months in the first stage and niacin sustained-release capsules for 3 months in the second stage. Dosage of niacin sustained-release capsules and placebo: 500mg once a day for week 1-4; The dose is 1000mg once a day for 5 to 12 weeks.

06

What researchers measure

Primary outcomes

  1. Changes in the percentages and counts of T cell subsets assessed by flow cytometry.

    Evaluating changes in the percentage of regular T cell subsets in peripheral blood before and after treatment by flow cytometry.

    Time frame: Baseline, 4 weeks and 12 weeks

Secondary outcomes

  1. Changes in disease Activity Score in 28 joints (DAS28) assessed by physician.

    Evaluating changes in DAS28 (Disease Activity Score 28) before and after treatment. DAS28 was calculated by the number of swollen joints (SJC) and tender joints (TJC) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (mm/h) or c-reactive protein (CRP) (mg/L), and patient's global assessment (PGA) of disease activity. Compared with the baseline, a lower DAS28 would mean an improvement in disease activity. Conversely, an increase in DAS28 indicates a deterioration in disease activity. The specific classification of activity levels is as follows:low activity (DAS28 \< 2.6), moderate activity (2.6 ≤ DAS28 ≤ 3.2), high activity (3.2 \< DAS28 ≤ 5.1), and extremely high activity (DAS28 \> 5.1)

    Time frame: Baseline,12 weeks

  2. Changes in the simplified disease activity index (SDAI) assessed by physician

    Evaluating changes in SDAI before and after treatment. The SDAI is a composite score based on the tender joints of 28 joints (TJC28), tender joints of 28 joints (SJC28), patients' and physicians' global assessments of disease activity, and c-reactive protein (CRP). Compared with the baseline, a lower SDAI would mean an improvement in disease activity. Conversely, an increase in SDAI indicates a deterioration in disease activity. The specific classification of activity levels is as follows:clinical remission (SDAI≤ 3.3), low activity (3.3 \< SDAI≤11), moderate activity (11 \< SDAI≤ 26), and high activity (SDAI\> 26)

    Time frame: Baseline and 12 weeks

  3. Changes in the clinical disease activity index (CDAI) assessed by physician

    Evaluating changes in CDAI before and after treatment. The Clinical Disease Activity Index (CDAI) is a composite score based on the TJC28, SJC28, and patients'and physicians'assessments. Compared with the baseline, a lower CDAI would mean an improvement in disease activity. Conversely, an increase in CDAI indicates a deterioration in disease activity. The specific classification of activity levels is as follows: clinical remission (CDAI≤ 2.8), low activity (2.8 \< CDAI≤10), moderate activity (10 \< CDAI≤ 22), and high activity (CDAI\> 22)

    Time frame: Baseline and 12 weeks

  4. ACR 20/50/70 response rate assessed by physician

    Proportion of patients with ACR20/50/70. The assessment was based on a 20%/50%/70% or greater improvement in the number of joint tenderness or joint swelling compared to baseline and a 20%/50%/70% or greater improvement in three of the remaining five core measures, which included: Patient's overall assessment of disease activity, physician's overall assessment of disease activity, patient's assessment of arthritis pain, HAQ-DI, and acute phase reactant levels (ESR vs. CRP).

    Time frame: Baseline and 12 weeks

Other outcomes

  1. Changes of triglyceride assessed by peripheral blood physiological parameter

    Evaluating the changes in triglyceride after treatment in peripheral blood.

    Time frame: Baseline, 4 weeks and 12 weeks

  2. Changes of cholesterol assessed by peripheral blood physiological parameter

    Evaluating changes in cholesterol after treatment in peripheral blood.

    Time frame: Baseline, 4 weeks and 12 weeks

  3. Changes in c-reactive protein (CRP) assessed by peripheral blood physiological parameter.

    Evaluating changes in concentration of CRP (mg/L) before and after treatment in peripheral blood.

    Time frame: Baseline, 4 weeks and 12 weeks

  4. Changes in erythrocyte sedimentation rate (ESR) assessed by peripheral blood physiological parameter.

    Evaluating changes in concentration of ESR (mm/h) before and after treatment in peripheral blood.

    Time frame: Baseline, 4 weeks and 12 weeks

  5. Changes in serum soluble cluster of differentiation 14 (sCD14) assessed by ELISA.

    Evaluating changes in sCD14 concentration in serum before and after treatment by ELISA.

    Time frame: Baseline, 4 weeks and 12 weeks

  6. Changes in serum lipopolysaccharide-binding protein (LBP) assessed by ELISA.

    Evaluating changes in LBP concentration in serum before and after treatment by ELISA.

    Time frame: Baseline, 4 weeks and 12 weeks

  7. Changes in serum intestinal fatty acid-binding protein (I-FABP) assessed by ELISA..

    Evaluating changes in I-FABP concentration in serum before and after treatment by ELISA.

    Time frame: Baseline, 4 weeks and 12 weeks

  8. Numbers of participants with treatment-related adverse events assessed by questionnaire.

    Adverse effects include fever, rash, abnormal liver and kidney function, new-onset infection, and any abnormal measures associated with experimental drugs were recorded by questionnaire.

    Time frame: 12 weeks

  9. Changes in intestinal flora assessed by fecal metagenomic sequencing.

    Evaluating the changes of intestinal flora before and after treatment by fecal metagenomic sequencing.

    Time frame: Baseline and 12 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for Jan 2027, 19 months later.

Of 42 non-industry phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 49. This study's planned 19 months is below that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2024
First posted
Jun 4, 2025
StartEst.
May 28, 2025
Primary completionEst.
Jan 3, 2027
CompletionEst.
Jun 15, 2027
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07004725
Responsible party
He Jing (Professor, Peking University People's Hospital) — Principal investigator
First posted
Jun 4, 2025
Start date
May 28, 2025 (estimated)
Primary completion
Jan 3, 2027 (estimated)
Completion
Jun 15, 2027 (estimated)
Last update
Jun 4, 2025

Study contacts

Jing He
Contact
hejing1105@126.com
010-88326666
Naidi Wang
Contact
pkuwnd@163.com
18811618179

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion